Cargando…

Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety

(1) Background: The authors present the first results of active raster-scanned carbon ion radiotherapy (CIRT) for radioresistant laryngeal malignancies regarding efficacy and toxicity. (2) Methods: 15 patients with laryngeal adenoid cystic carcinoma (ACC; n = 8; 53.3%) or chondrosarcoma (CS; n = 7;...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbaba, Sati, Lang, Kristin, Held, Thomas, Bulut, Olcay Cem, Mattke, Matthias, Uhl, Matthias, Jensen, Alexandra, Plinkert, Peter, Rieken, Stefan, Herfarth, Klaus, Debus, Juergen, Adeberg, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211114/
https://www.ncbi.nlm.nih.gov/pubmed/30340397
http://dx.doi.org/10.3390/cancers10100388
_version_ 1783367271758954496
author Akbaba, Sati
Lang, Kristin
Held, Thomas
Bulut, Olcay Cem
Mattke, Matthias
Uhl, Matthias
Jensen, Alexandra
Plinkert, Peter
Rieken, Stefan
Herfarth, Klaus
Debus, Juergen
Adeberg, Sebastian
author_facet Akbaba, Sati
Lang, Kristin
Held, Thomas
Bulut, Olcay Cem
Mattke, Matthias
Uhl, Matthias
Jensen, Alexandra
Plinkert, Peter
Rieken, Stefan
Herfarth, Klaus
Debus, Juergen
Adeberg, Sebastian
author_sort Akbaba, Sati
collection PubMed
description (1) Background: The authors present the first results of active raster-scanned carbon ion radiotherapy (CIRT) for radioresistant laryngeal malignancies regarding efficacy and toxicity. (2) Methods: 15 patients with laryngeal adenoid cystic carcinoma (ACC; n = 8; 53.3%) or chondrosarcoma (CS; n = 7; 46.7%) who underwent radiotherapy with carbon ions (C12) at the Heidelberg Ion Beam Therapy Center (HIT) between 2013 and 2018 were identified retrospectively and analyzed for local control (LC), overall survival (OS), and distant progression-free survival using the Kaplan–Meier method. CIRT was applied either alone (n = 7, 46.7%) or in combination with intensity modulated radiotherapy (IMRT) (n = 8, 53.3%). The toxicity was assessed according to the Common Toxicity Terminology Criteria for Adverse Events (CTCAE) v4.03. (3). Results: the median follow-up was 24 months (range 5–61 months). Overall, the therapy was tolerated very well. No grade >3 acute and chronic toxicity could be identified. The most reported acute grade 3 side effects were acute dysphagia (n = 2; 13%) and acute odynophagia (n = 3; 20%), making supportive nutrition via gastric tube (n = 2; 13.3%) and via high caloric drinks (n = 1; 6.7%) necessary due to swallowing problems (n = 4; 27%). Overall, chronic grade 3 toxicity in the form of chronic hoarseness occurred in 7% of the patients (n = 1; 7%). At the last follow-up, all the patients were alive. No local or locoregional recurrence could be identified. Only one patient with laryngeal ACC developed lung metastases three years after the first diagnosis. (4) Conclusions: the accelerated hypofractionated active raster-scanned carbon ion radiotherapy for radioresistant laryngeal malignancies is feasible in practice with excellent local control rates and moderate acute and late toxicity. Further follow-ups are necessary to evaluate the long-term clinical outcome.
format Online
Article
Text
id pubmed-6211114
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62111142018-11-02 Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety Akbaba, Sati Lang, Kristin Held, Thomas Bulut, Olcay Cem Mattke, Matthias Uhl, Matthias Jensen, Alexandra Plinkert, Peter Rieken, Stefan Herfarth, Klaus Debus, Juergen Adeberg, Sebastian Cancers (Basel) Article (1) Background: The authors present the first results of active raster-scanned carbon ion radiotherapy (CIRT) for radioresistant laryngeal malignancies regarding efficacy and toxicity. (2) Methods: 15 patients with laryngeal adenoid cystic carcinoma (ACC; n = 8; 53.3%) or chondrosarcoma (CS; n = 7; 46.7%) who underwent radiotherapy with carbon ions (C12) at the Heidelberg Ion Beam Therapy Center (HIT) between 2013 and 2018 were identified retrospectively and analyzed for local control (LC), overall survival (OS), and distant progression-free survival using the Kaplan–Meier method. CIRT was applied either alone (n = 7, 46.7%) or in combination with intensity modulated radiotherapy (IMRT) (n = 8, 53.3%). The toxicity was assessed according to the Common Toxicity Terminology Criteria for Adverse Events (CTCAE) v4.03. (3). Results: the median follow-up was 24 months (range 5–61 months). Overall, the therapy was tolerated very well. No grade >3 acute and chronic toxicity could be identified. The most reported acute grade 3 side effects were acute dysphagia (n = 2; 13%) and acute odynophagia (n = 3; 20%), making supportive nutrition via gastric tube (n = 2; 13.3%) and via high caloric drinks (n = 1; 6.7%) necessary due to swallowing problems (n = 4; 27%). Overall, chronic grade 3 toxicity in the form of chronic hoarseness occurred in 7% of the patients (n = 1; 7%). At the last follow-up, all the patients were alive. No local or locoregional recurrence could be identified. Only one patient with laryngeal ACC developed lung metastases three years after the first diagnosis. (4) Conclusions: the accelerated hypofractionated active raster-scanned carbon ion radiotherapy for radioresistant laryngeal malignancies is feasible in practice with excellent local control rates and moderate acute and late toxicity. Further follow-ups are necessary to evaluate the long-term clinical outcome. MDPI 2018-10-18 /pmc/articles/PMC6211114/ /pubmed/30340397 http://dx.doi.org/10.3390/cancers10100388 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Akbaba, Sati
Lang, Kristin
Held, Thomas
Bulut, Olcay Cem
Mattke, Matthias
Uhl, Matthias
Jensen, Alexandra
Plinkert, Peter
Rieken, Stefan
Herfarth, Klaus
Debus, Juergen
Adeberg, Sebastian
Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
title Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
title_full Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
title_fullStr Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
title_full_unstemmed Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
title_short Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety
title_sort accelerated hypofractionated active raster-scanned carbon ion radiotherapy (cirt) for laryngeal malignancies: feasibility and safety
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211114/
https://www.ncbi.nlm.nih.gov/pubmed/30340397
http://dx.doi.org/10.3390/cancers10100388
work_keys_str_mv AT akbabasati acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT langkristin acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT heldthomas acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT bulutolcaycem acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT mattkematthias acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT uhlmatthias acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT jensenalexandra acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT plinkertpeter acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT riekenstefan acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT herfarthklaus acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT debusjuergen acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety
AT adebergsebastian acceleratedhypofractionatedactiverasterscannedcarbonionradiotherapycirtforlaryngealmalignanciesfeasibilityandsafety